AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Company’s Profile:
Kinnate Biopharma Inc. is a clinical-stage precision oncology firm established with the overarching goal of instilling hope in individuals grappling with cancer through the advancement of targeted therapies. Focused on identified oncogenic drivers lacking approved targeted treatments, the company endeavors to surmount the constraints linked with current cancer therapies, including ineffectiveness or the emergence of acquired and intrinsic resistance.
Acquisition Agreement:
On February 16, 2024, Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology entity, disclosed the execution of a definitive merger agreement ("Merger Agreement") with XOMA Corporation ("XOMA"). This agreement outlines XOMA's acquisition of Kinnate at a per-share price of Kinnate common stock ("Kinnate common stock") ranging between USD 2.3352 and USD 2.5879 in cash. The specified price comprises a base cash component of USD 2.3352 per share along with an additional cash amount of up to USD 0.2527 per share. Additionally, each share includes one non-transferable contingent value right, offering entitlement to (a) 100% of the net proceeds from any divestment of Kinnate's investigational pan-RAF inhibitor, exarafenib, and/or other pan-RAF inhibitors before the merger's closure, and (b) 85% of the net proceeds from any divestment of other Kinnate assets executed before or within one year from the closure, received within five years post-closure under a definitive contingent value rights agreement.
Approval and Recommendation
A specialized committee of impartial and autonomous members ("Special Committee") of Kinnate's Board of Directors ("Board"), aided by legal and financial advisors, meticulously evaluated the proposition. Subsequently, the disinterested and independent Board members unanimously concluded that XOMA's acquisition is conducive to the interests of all Kinnate shareholders. Upon the Special Committee's unanimous recommendation, the Board endorsed the Merger Agreement and associated transactions.
Transaction Execution
In accordance with the Merger Agreement's stipulations, a wholly owned XOMA subsidiary will initiate a tender offer ("Offer") by March 4, 2024, targeting all outstanding shares of Kinnate common stock. The Offer's completion hinges on several conditions, including the tender of Kinnate common stock constituting at least a majority of the total outstanding shares, the availability of a minimum of USD 120 million in cash (net of transaction expenses, wind-down expenses, and other obligations) upon closure, and standard closing conditions. Notably, Kinnate officers, directors, and shareholders, collectively holding approximately 46% of Kinnate common stock, have entered into support agreements, pledging to tender their shares in the Offer and back the merger transaction. Anticipated to finalize in the first half of 2024, the merger transaction promises to bring significant strategic implications for both entities involved.
This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services. Please note past performance is neither an indicator nor a guarantee of future performance.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.
Please wait processing your request...